The global pharmaceutical industry experienced a 15% drop in company filings mentions of big data in Q2 2023 compared with the previous quarter, with the highest share accounted for by Hangzhou Tigermed Consulting with 80% year-on-year increase, according to GlobalData’s analysis of over 383 pharmaceutical company filings. The big data landscape is rapidly evolving and pharma companies are increasingly integrating big data analytics into their value chains. GlobalData’s Big Data in Pharmaceuticals – Thematic Research report offers an overview of the current landscape, trends, and leading companies, and highlights the opportunities for the use of big data analytics in the future. Buy the report here.
Notably, big data was one of the most frequently referenced themes in Q2 2023, ranking highest in terms of mentions, ahead of precision and personalized medicine and artificial intelligence, according to GlobalData.
Of the top leading companies in the pharmaceutical industry, Hangzhou Tigermed Consulting had the greatest increase in references for big data in Q2 2023, compared with the previous quarter. GlobalData identified nine big data-related sentences in the company's filings - 1% of all sentences - and an increase of 80% in Q2 2023 compared with Q2 2022. Novartis’s mentions of big data rose by 500% to 6 and Merck’s by 69% to 5 and Viatris’s by 100% to 4 and Amgen’s by 50% to 3.
GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for big data in Q2 2023 was 84.
For further understanding of GlobalData's Big Data in Pharmaceuticals - Thematic Research buy the report here.